title: 4-Azetidinyl-1-heteroatom linked cyclohexane antagonists of CCR2: patent evaluation.
abstract: This application discloses a series of di- and tri-substituted cyclohexanes as CCR2 receptor antagonists which are stated to be useful in treating inflammation and autoimmune diseases, such as type 2 diabetes and asthma. Although receptor binding of the compounds to CCR2 is demonstrated, there are no data to support the idea that these molecules are functional antagonists.
authors.affiliation: UC Davis, Department of Pharmacology, Davis CA 9561, USA. rhoruk@ucdavis.edu
authors.forename: Richard
authors.initials: R
authors.lastname: Horuk
authors.forename: William
authors.initials: W
authors.lastname: Guilford
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry / Q000494:pharmacology*; D015551:Autoimmunity / Q000187:drug effects; D003510:Cyclohexanes / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007155:Immunologic Factors / Q000737:chemistry / Q000494:pharmacology*; D010330:Patents as Topic; D054390:Receptors, CCR2 / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
chemical_list: D000893:Anti-Inflammatory Agents; D003510:Cyclohexanes; D007155:Immunologic Factors; D054390:Receptors, CCR2